Comparing BioLife Solutions (BLFS) & Its Rivals

BioLife Solutions (NASDAQ: BLFS) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare BioLife Solutions to similar businesses based on the strength of its institutional ownership, dividends, profitability, analyst recommendations, valuation, risk and earnings.

Insider & Institutional Ownership

2.6% of BioLife Solutions shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are held by institutional investors. 37.7% of BioLife Solutions shares are held by insiders. Comparatively, 11.9% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


This table compares BioLife Solutions and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLife Solutions -63.71% -64.98% -35.19%
BioLife Solutions Competitors -2,874.53% -68.34% -9.05%

Analyst Recommendations

This is a summary of current recommendations for BioLife Solutions and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions 0 0 2 0 3.00
BioLife Solutions Competitors 834 3736 6765 183 2.55

BioLife Solutions presently has a consensus target price of $6.00, indicating a potential upside of 5.26%. As a group, “Pharmaceuticals” companies have a potential upside of 28.32%. Given BioLife Solutions’ competitors higher probable upside, analysts clearly believe BioLife Solutions has less favorable growth aspects than its competitors.

Risk and Volatility

BioLife Solutions has a beta of -0.8, indicating that its share price is 180% less volatile than the S&P 500. Comparatively, BioLife Solutions’ competitors have a beta of 0.90, indicating that their average share price is 10% less volatile than the S&P 500.

Valuation & Earnings

This table compares BioLife Solutions and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
BioLife Solutions $9.31 million -$2.21 million -12.13
BioLife Solutions Competitors $8.20 billion $2.68 billion -0.76

BioLife Solutions’ competitors have higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


BioLife Solutions competitors beat BioLife Solutions on 7 of the 12 factors compared.

About BioLife Solutions

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.

Receive News & Ratings for BioLife Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions Inc. and related companies with's FREE daily email newsletter.

Leave a Reply